Page 1

THE GENE THERAPY EXPLORER " CombiGene's epilepsy project CG01 continues to show strength . At the end of the second quarter of the year , as many as four value - creating milestones were achieved : the release of plasmids for GMP production , completed GMP production , initiated optimization of the administration of CG01 in large animal studies , and the approval of patents in the U.S. and Russia . " Jan Nilsson CEO Interim report January - June 2021 for CombiGene AB ( publ ) CombiGene